CDK4/6 inhibition in hormone receptor-positive/HER2-negative breast cancer: Biological and clinical aspects

Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial.

(2023) Antonio Llombart-Cussac et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: MAINTAIN Trial

(2023) Kevin Kalinsky et al.   JOURNAL OF CLINICAL ONCOLOGY

CDK4/6 inhibitors and the pRB-E2F1 axis suppress PVR and PD-L1 expression in triple-negative breast cancer

(2023) Mariusz Shrestha et al.   Oncogenesis

Overall Survival With Palbociclib And Fulvestrant in Women With HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-Blind, Phase 3 Randomized Study

(2022) Massimo Cristofanilli et al.   CLINICAL CANCER RESEARCH

FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer

(2022) Melanie Royce et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer

(2022) Gabriel N. Hortobagyi et al.   NEW ENGLAND JOURNAL OF MEDICINE

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

(2022) Marta Palafox et al.   Nature Communications

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

(2022) Stephen R D Johnston et al.   LANCET ONCOLOGY

Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1

(2022) Masakazu Toi et al.   ONCOLOGIST

The AMBRA1 E3 ligase adaptor regulates the stability of cyclin D

(2021) Andrea C. Chaikovsky et al.   NATURE

CRL4AMBRA1 is a master regulator of D-type cyclins

(2021) Daniele Simoneschi et al.   NATURE

CDK4/6 inhibition promotes anti-tumor immunity through the induction of T cell memory

(2021) Emily J Lelliott et al.   Cancer Discovery

Inhibition of CDK4/6 promotes CD8 T-cell memory formation

(2021) Max Heckler et al.   Cancer Discovery

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

(2021) D.J. Slamon et al.   ANNALS OF ONCOLOGY

Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2

(2021) Lindsey R. Pack et al.   Nature Communications

Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial

(2021) Yen-Shen Lu et al.   CLINICAL CANCER RESEARCH

Abemaciclib is a potent inhibitor of DYRK1A and HIP kinases involved in transcriptional regulation

(2021) Ines H. Kaltheuner et al.   Nature Communications

Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future

(2020) Laura M Spring et al.   LANCET

c-myc regulates the sensitivity of breast cancer cells to palbociclib via c-myc/miR-29b-3p/CDK6 axis

(2020) Wenfei Ji et al.   Cell Death & Disease

Sustained mTORC1 activity during palbociclib-induced growth arrest triggers senescence in ER+ breast cancer cells

(2020) Reeja S. Maskey et al.   CELL CYCLE

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

(2019) George W. Sledge et al.   JAMA Oncology

Can CDK4/6 inhibitors cause fatal lung injury?

(2019) Khalid A. Jazieh et al.   Expert Review of Anticancer Therapy

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

(2019) Dennis J. Slamon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

(2018) G N Hortobagyi et al.   ANNALS OF ONCOLOGY

CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought

(2018) Mary E. Klein et al.   CANCER CELL

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

(2017) George W. Sledge et al.   JOURNAL OF CLINICAL ONCOLOGY

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

(2017) Matthew P. Goetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling

(2017) Emily M. Cousins et al.   MOLECULAR CANCER RESEARCH

CDK4/6 inhibition triggers anti-tumour immunity

(2017) Shom Goel et al.   NATURE

Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance

(2017) Jinfang Zhang et al.   NATURE

The metabolic function of cyclin D3–CDK6 kinase in cancer cell survival

(2017) Haizhen Wang et al.   NATURE

ATRX is a regulator of therapy induced senescence in human cells

(2017) Marta Kovatcheva et al.   Nature Communications

Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance

(2016) P. Chen et al.   MOLECULAR CANCER THERAPEUTICS

MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition

(2015) Marta Kovatcheva et al.   Oncotarget

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

(2014) Lawrence M. Gelbert et al.   INVESTIGATIONAL NEW DRUGS